Widespread bisphosphonate (BP) use to treat various medical conditions led to increased recognition of their possible association with osteonecrosis (ON) of the jaw. BPs are synthetic pyrophosphate analogs used to treat hypercalcemia secondary to malignancy, osteoporosis, multiple myeloma, Paget disease, osteosclerosis, fibrous dysplasia, and other bone diseases in which bone resorption is involved. Infrequent side effects with BP use include pyrexia, renal function impairment, hypocalcemia, and recently recognized avascular ON of the jaw. The American Society of Bone and Mineral Research defined BP-related jaw ON as current or previous treatment with BPs that leads to exposed bone in the maxillofacial region that does not heal within 8 weeks of identification by a healthcare provider, and the patient has no history of radiation therapy in the craniofacial region. Eight weeks is considered because most surgical and infectious sites heal in this time frame even if complications such as postsurgical infection, chemotherapy, or systemic diseases are present.
Mechanism of Action of Bisphosphonate
BPs disrupts the bone remodeling cycle by reducing osteoclast survival and function. BPs accumulate at the site of active bone formation and get internalized by osteoclasts, which makes bone resistant to dissolution by osteoclast, reduce osteoclast survival, and modulate the signaling from osteoblast to osteoclast.
Bone Remodeling Cycle
Without resorption and new bone formation, old bone survives beyond its lifespan, and capillary network in bone is not maintained, leading to avascular necrosis of the jaw. Also, high potency BPs can lead to necrosis by the toxicity of soft tissue along with cells of bone which is further complicated by infection. Due to altered wound healing, delayed epithelial closure of a mucosal opening in the mouth leads to chronic infection and the necrosis of bone. So far, there is no evidence from prospective controlled trials to show the relationship between BPs and ON of the jaw.
The prospective data on the incidence of BP associated ON of jaw is limited and is mostly based on retrospective studies and case reports with limited sample sizes because of the lower frequency of events and only recent widespread attention of the condition. The probability of BP associated ON of jaw depends upon BP kind, duration and dosage of BP involved, baseline condition for which BP therapy is given and the location involved.
Intravenous (IV) versus oral BPs
ON of jaw is mostly reported with the use of more potent nitrogen-containing BPs like zoledronic acid and pamidronate. Incidence is higher with zoledronic acid due to a greater reduction of collagen type-1 degradation products (N-telopeptide) causing stronger antiresorptive activity leading to a decrease in bone turnover.
Oral BP induced ON is rare, less aggressive and respond better to treatment compared to iv BP induced ON. The difference is due to low lipid solubility of oral BPs that limits small intestinal absorption and much more slower accumulation in bone.
Dose and duration
The incidence of ON is related to dose and duration of BPs and increases with a higher dose of potent BPs being administered for a longer duration. As per reported data, cautious use of zoledronic acid and pamidronate is required after 2 years. Risk of bone necrosis with BP therapy ranged from greater than 1% at 12 months to 11% at 4 years and with zoledronic acid alone, the risk from within 1% in the first-year rise to 21% at 3 years. Due to slower accumulation of oral BPs, no clinically exposed bone appear until after 3-year exposure and incidence and severity increases with each additional year of drug use.
Osteoporosis and oncology patients
As per current data, the incidence of BP-induced ON in osteoporosis patients is very low, ranging from 0.15% to less than 0.001% person-years of exposure and may be only slightly higher than the general population. The incidence of BP-induced ON in oncology patient with bone metastasis is much higher as they are exposed to more intensive osteoclast inhibition and bone necrosis have mostly occurred due to use of high dose IV BPs. Also, the frequency varies with the underlying condition being treated. Wang et al. did a 5-year retrospective study of 292 patients who were treated with IV BPs for the incidence of ON of the jaw and found 3% to 8% patient with multiple myeloma, 2% to 5% with breast cancer and 2.9% with prostate cancer developed ON. Also, Abu-Id et al. did a retrospective study on the development of BP-induced ON of the jaw and found it occurred in 2% to 11% of multiple myeloma patients, 1% to 7% of breast cancer patients and 6% to 15% of prostate cancer patients.
BPs induced ON of jaw occurs more frequently in the mandible than maxilla and almost always began in alveolar bone due to it’s greater bone turnover rate. It results from greater reliance on osteoclast related remodeling due to occlusion and denture wearing pressure and tension forces. Most common sites are nonhealing dentoalveolar sites, traumatized palatal & mandibular tori and exposed portions of the mylohyoid ridge.
Incidence of BP-induced ON of the jaw increases with:
Several factors increase the risk of developing ON with BP use.
BP-Induced ON of Jaw Risk Factors
The necrotic bone may remain asymptomatic for a prolonged period or may become symptomatic mostly due to localized inflammation of soft tissue. The most common symptoms are pain, surrounding tissue swelling, erythema, necrotic bone infection, suppuration, and lose teeth. Comorbidities include tissue ulceration, intra-and extraoral sinus tracts, and fistula formation and in few cases, it is associated with impairment of nerve function. Some patients presented with altered nerve sensation due to compression of the neurovascular bundle. Paresthesia or even anesthesia of the associated branch of the trigeminal nerve can occur. An important early symptom of BP-induced ON of the jaw that can be easily detected is hypoesthesia or anesthesia of the lower lip. Chronic maxillary sinusitis in patients with maxillary bone involvement and pathological fracture in edentulous patients with oral implants can be other complication associated with it.
Radiographically, BP induced ON of jaw can range from no alterations to varying radiolucencies or radio-opacities. Frequently seen osteolytic lesions may appear less or more radiodense providing similar radiographic appearance as in bone metastasis. Radiographic appearance of ON of the jaw may include altered bone morphology, increased bone density, sequestration, or periosteal bone formation. Symptoms may be spontaneous or following dentoalveolar surgery, in edentulous regions of the jaw or at sites of exostoses in oncology patients.
Signs and Symptoms
Early identification of BP associated ON can be very challenging but is important for disease prevention and patient care.
Patient history and clinical finding of exposed bone for 8 weeks or longer that does not respond to appropriate treatment is the diagnostic hallmark of BP associated ON of jaw. Symptoms may vary from patient being asymptomatic in the early phase to presence of symptoms like pain, soft tissue inflammation, erythema, ulceration, paraesthesia as the disease progress and in advanced cases sequestration, the formation of sinus tracts and fistula along with pathological fractures can be seen.
Resected necrotic bone from BP associated ON patients does not demonstrate any unique features of the disease/ Most frequently found microorganisms in the exposed bone sites are Actinomyces, Veillonella, Eikenella, and Moraxella species and all of them are penicillin-sensitive organisms. Presence of sulfur granules in deeper tissue and drainage areas supports the diagnosis of actinomycosis and requires appropriate treatment.
Blood Test Finding
It measures C-terminal telopeptide (CTX) value which depicts the level of octapeptide fragment released due to osteoclastic bone resorption from type I bone collagen. Its levels are related to the number of ON of jaw lesions, stage of disease, and is an index of bone turnover. A lower value represents a high-risk patient with suppressed bone turnover and reduced healing capacity. CTX less than 100 pg/ml equals high risk, 100 to 150 pg/ml equal moderate risk, and greater than 150 pg/ml equal minimal or no risk.
It is very similar to that observed in bone metastasis. Osteolytic lesions are frequently seen that may vary in radiodensity than unaffected bone. Early radiographic signs along alveolar bone may include widened periodontal ligament space and sclerosis of lamina dura.
Imaging Modalities and Diagnostic Tests
Due to nonspecific radiographic features of BP associated ON of jaw, imaging provides a good evaluation of the area involved and can assist in identifying the extent of bone and soft tissue disease but do not provide any definitive differentiation of ON of the jaw from other conditions.
Combinational approaches as use of CBCT with scintigraphy for diagnosing osteomyelitis or use of contrast agents with MRI, sequential imaging and the manipulation of image planes can all be helpful measures to diagnose early or preclinical stages of BP-induced ON.
Treatment is dependent upon many variables like age, gender, disease stage and lesion size, comorbidities present, medication exposure among others, but since their influence on disease course and treatment response is not known, clinical judgment guides the treatment approach. Other important factors are prognosis, life quality and expectancy and ability of an individual to cope with the disease. No evidence-based guidelines for treatment of BP-induced ON of the jaw are currently available, but the treatment goal is to alleviate pain, control infection and stabilize the progression of exposed bone.
Lack of symptomatic or radiographic improvement with various treatment modalities indicate permanent bone defect and need surgical intervention.
The various treatment approaches included are use of hyperbaric oxygen, bone marrow stem cell intralesional transplantation, local application of platelet-derived growth factor, low-level laser therapy, or using them in combination with conservative and/or surgical debridement but their effect on the treatment outcome needs further substantiation.
Most recent recommendations advocate non-surgical treatment approach due to impaired wound healing, but few studies included radical resection to viable bone and hermetic wound closure with soft tissue being the only curative approach. Combination of various approaches like marginal resection along with the use of platelet-derived growth factor had been advocated by many studies.
Treatment Approach Review
The presence of exposed bone characterizes BP associate ON of the jaw. In the absence of exposed bone, the differential diagnosis includes conditions such as periodontal and periapical pathosis, sinusitis, gingivitis or mucositis, temporomandibular disorders, osteomyelitis, metastatic bone tumors, osteonecrosis induced by neuralgia and osteoradionecrosis. The differential diagnosis for conditions including exposed bone but without the BP use are cement osseous dysplasia with secondary sequestration, trauma, infectious osteomyelitis, osteonecrosis following Herpes zoster infection or HIV associated necrotizing ulcerative periodontitis.
Very little evidence is reviewed for the staging of BP associated ON of jaw. So staging recommendations should be considered as consensus statements. The current staging system is developed by Ruggiero and colleagues and is adopted by AAOMS. Stage system is important to identify stage characteristics and provide appropriate diagnosis and management.
Stage 1 patients have exposed bone and are asymptomatic with no localized soft tissue infection. Stage 2 patients have exposed bone and have pain and regional soft tissue inflammation or infection. Stage 3 patients have exposed bone with associated pain, localized soft tissue inflammation, or secondary infection along with pathologic fracture, the formation of extraoral or oral-antral fistula and radiographically have osteolysis extending to the inferior mandibular border or maxillary sinus floor. Recently, AAOMS added stage 0 to the staging system that has patients who take BPs and present with non-specific clinical findings and symptoms. Term stage 0 can lead to overdiagnosis that can have detrimental effects on the patient’s skeletal health if modification of anti-resorptive medication regimen is done as similar presenting symptoms may lead to a different diagnosis.
Prevention is the best approach and requires good communication among dentist, oral surgeon, physicians, nurse practitioners, and oncologists to develop measures aimed at preventing the development of BP-induced ON of the jaw.
Recommendations Before Initiating BP Therapy
Around 4 to 6 monthly doses are required to have significant effects on bone healing in jaws; it is recommended to take preventive measures during this period.
Recommendations for Patients Receiving BP Therapy
After 4 to 6 doses of BP, bone turnover is significantly suppressed, making bone healing unpredictable and risky for ON.
Prompt recognition of osteonecrosis by the interprofessional team is important for improving outcomes. Prescribing providers include primary care providers, dentists, orthopedists, rheumatologists, and oncologists. Pharmacists provided education to patients and their families, monitor compliance, and provide feedback to the team. Specialty care nurses including infusion nurses, orthopedic nurses, and otolaryngology provide education, monitor patients, and inform the team about status changes or issues. Good communication among the team, patient education, appropriate preventive measures, and treatment aimed at pain and infection control can enhance the patient care outcomes for patients on bisphosphonates who are at the risk of developing or having established osteonecrosis of the jaw. [Level 5]
|||Shane E,Goldring S,Christakos S,Drezner M,Eisman J,Silverman S,Pendrys D, Osteonecrosis of the jaw: more research needed. Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research. 2006 Oct [PubMed PMID: 16995804]|
|||McClung MR, Bisphosphonates. Endocrinology and metabolism clinics of North America. 2003 Mar [PubMed PMID: 12699302]|
|||Khosla S,Burr D,Cauley J,Dempster DW,Ebeling PR,Felsenberg D,Gagel RF,Gilsanz V,Guise T,Koka S,McCauley LK,McGowan J,McKee MD,Mohla S,Pendrys DG,Raisz LG,Ruggiero SL,Shafer DM,Shum L,Silverman SL,Van Poznak CH,Watts N,Woo SB,Shane E, Bisphosphonate-associated osteonecrosis of the jaw: report of a task force of the American Society for Bone and Mineral Research. Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research. 2007 Oct [PubMed PMID: 17663640]|
|||Lehenkari PP,Kellinsalmi M,Näpänkangas JP,Ylitalo KV,Mönkkönen J,Rogers MJ,Azhayev A,Väänänen HK,Hassinen IE, Further insight into mechanism of action of clodronate: inhibition of mitochondrial ADP/ATP translocase by a nonhydrolyzable, adenine-containing metabolite. Molecular pharmacology. 2002 May [PubMed PMID: 11961144]|
|||Rogers MJ,Gordon S,Benford HL,Coxon FP,Luckman SP,Monkkonen J,Frith JC, Cellular and molecular mechanisms of action of bisphosphonates. Cancer. 2000 Jun 15 [PubMed PMID: 10898340]|
|||Reid IR,Bolland MJ,Grey AB, Is bisphosphonate-associated osteonecrosis of the jaw caused by soft tissue toxicity? Bone. 2007 Sep [PubMed PMID: 17572168]|
|||Rizzoli R,Burlet N,Cahall D,Delmas PD,Eriksen EF,Felsenberg D,Grbic J,Jontell M,Landesberg R,Laslop A,Wollenhaupt M,Papapoulos S,Sezer O,Sprafka M,Reginster JY, Osteonecrosis of the jaw and bisphosphonate treatment for osteoporosis. Bone. 2008 May [PubMed PMID: 18314405]|
|||Rosen LS,Gordon D,Kaminski M,Howell A,Belch A,Mackey J,Apffelstaedt J,Hussein M,Coleman RE,Reitsma DJ,Seaman JJ,Chen BL,Ambros Y, Zoledronic acid versus pamidronate in the treatment of skeletal metastases in patients with breast cancer or osteolytic lesions of multiple myeloma: a phase III, double-blind, comparative trial. Cancer journal (Sudbury, Mass.). 2001 Sep-Oct [PubMed PMID: 11693896]|
|||Marx RE,Cillo JE Jr,Ulloa JJ, Oral bisphosphonate-induced osteonecrosis: risk factors, prediction of risk using serum CTX testing, prevention, and treatment. Journal of oral and maxillofacial surgery : official journal of the American Association of Oral and Maxillofacial Surgeons. 2007 Dec [PubMed PMID: 18022461]|
|||Cartsos VM,Zhu S,Zavras AI, Bisphosphonate use and the risk of adverse jaw outcomes: a medical claims study of 714,217 people. Journal of the American Dental Association (1939). 2008 Jan [PubMed PMID: 18167381]|
|||Fellows JL,Rindal DB,Barasch A,Gullion CM,Rush W,Pihlstrom DJ,Richman J, ONJ in two dental practice-based research network regions. Journal of dental research. 2011 Apr [PubMed PMID: 21317245]|
|||Lyles KW,Colón-Emeric CS,Magaziner JS,Adachi JD,Pieper CF,Mautalen C,Hyldstrup L,Recknor C,Nordsletten L,Moore KA,Lavecchia C,Zhang J,Mesenbrink P,Hodgson PK,Abrams K,Orloff JJ,Horowitz Z,Eriksen EF,Boonen S, Zoledronic acid and clinical fractures and mortality after hip fracture. The New England journal of medicine. 2007 Nov 1 [PubMed PMID: 17878149]|
|||Powell D,Bowler C,Roberts T,Garton M,Matthews C,McCall I,Davie M, Incidence of serious side effects with intravenous bisphosphonate: a clinical audit. QJM : monthly journal of the Association of Physicians. 2012 Oct [PubMed PMID: 22753670]|
|||Sieber P,Lardelli P,Kraenzlin CA,Kraenzlin ME,Meier C, Intravenous bisphosphonates for postmenopausal osteoporosis: safety profiles of zoledronic acid and ibandronate in clinical practice. Clinical drug investigation. 2013 Feb [PubMed PMID: 23184667]|
|||Wang EP,Kaban LB,Strewler GJ,Raje N,Troulis MJ, Incidence of osteonecrosis of the jaw in patients with multiple myeloma and breast or prostate cancer on intravenous bisphosphonate therapy. Journal of oral and maxillofacial surgery : official journal of the American Association of Oral and Maxillofacial Surgeons. 2007 Jul [PubMed PMID: 17577497]|
|||Abu-Id MH,Warnke PH,Gottschalk J,Springer I,Wiltfang J,Acil Y,Russo PA,Kreusch T, [PubMed PMID: 18234504]|
|||Marx RE,Sawatari Y,Fortin M,Broumand V, Bisphosphonate-induced exposed bone (osteonecrosis/osteopetrosis) of the jaws: risk factors, recognition, prevention, and treatment. Journal of oral and maxillofacial surgery : official journal of the American Association of Oral and Maxillofacial Surgeons. 2005 Nov [PubMed PMID: 16243172]|
|||Mellal A,Wiskott HW,Botsis J,Scherrer SS,Belser UC, Stimulating effect of implant loading on surrounding bone. Comparison of three numerical models and validation by in vivo data. Clinical oral implants research. 2004 Apr [PubMed PMID: 15008937]|
|||Hess LM,Jeter JM,Benham-Hutchins M,Alberts DS, Factors associated with osteonecrosis of the jaw among bisphosphonate users. The American journal of medicine. 2008 Jun [PubMed PMID: 18501224]|
|||Jadu F,Lee L,Pharoah M,Reece D,Wang L, A retrospective study assessing the incidence, risk factors and comorbidities of pamidronate-related necrosis of the jaws in multiple myeloma patients. Annals of oncology : official journal of the European Society for Medical Oncology. 2007 Dec [PubMed PMID: 17804475]|
|||Sedghizadeh PP,Kumar SK,Gorur A,Schaudinn C,Shuler CF,Costerton JW, Microbial biofilms in osteomyelitis of the jaw and osteonecrosis of the jaw secondary to bisphosphonate therapy. Journal of the American Dental Association (1939). 2009 Oct [PubMed PMID: 19797556]|
|||Lesclous P,Abi Najm S,Carrel JP,Baroukh B,Lombardi T,Willi JP,Rizzoli R,Saffar JL,Samson J, Bisphosphonate-associated osteonecrosis of the jaw: a key role of inflammation? Bone. 2009 Nov [PubMed PMID: 19631301]|
|||Hikita H,Miyazawa K,Tabuchi M,Kimura M,Goto S, Bisphosphonate administration prior to tooth extraction delays initial healing of the extraction socket in rats. Journal of bone and mineral metabolism. 2009 [PubMed PMID: 19436946]|
|||Landesberg R,Woo V,Cremers S,Cozin M,Marolt D,Vunjak-Novakovic G,Kousteni S,Raghavan S, Potential pathophysiological mechanisms in osteonecrosis of the jaw. Annals of the New York Academy of Sciences. 2011 Feb [PubMed PMID: 21291478]|
|||Ravosa MJ,Ning J,Liu Y,Stack MS, Bisphosphonate effects on the behaviour of oral epithelial cells and oral fibroblasts. Archives of oral biology. 2011 May [PubMed PMID: 21146154]|
|||Marini F,Tonelli P,Cavalli L,Cavalli T,Masi L,Falchetti A,Brandi ML, Pharmacogenetics of bisphosphonate-associated osteonecrosis of the jaw. Frontiers in bioscience (Elite edition). 2011 Jan 1 [PubMed PMID: 21196316]|
|||English BC,Baum CE,Adelberg DE,Sissung TM,Kluetz PG,Dahut WL,Price DK,Figg WD, A SNP in CYP2C8 is not associated with the development of bisphosphonate-related osteonecrosis of the jaw in men with castrate-resistant prostate cancer. Therapeutics and clinical risk management. 2010 Nov 19 [PubMed PMID: 21151627]|
|||Sarasquete ME,García-Sanz R,Marín L,Alcoceba M,Chillón MC,Balanzategui A,Santamaria C,Rosiñol L,de la Rubia J,Hernandez MT,Garcia-Navarro I,Lahuerta JJ,González M,San Miguel JF, Bisphosphonate-related osteonecrosis of the jaw is associated with polymorphisms of the cytochrome P450 CYP2C8 in multiple myeloma: a genome-wide single nucleotide polymorphism analysis. Blood. 2008 Oct 1 [PubMed PMID: 18594024]|
|||Allen MR,Ruggiero SL, Higher bone matrix density exists in only a subset of patients with bisphosphonate-related osteonecrosis of the jaw. Journal of oral and maxillofacial surgery : official journal of the American Association of Oral and Maxillofacial Surgeons. 2009 Jul [PubMed PMID: 19531405]|
|||Otto S,Hafner S,Grötz KA, The role of inferior alveolar nerve involvement in bisphosphonate-related osteonecrosis of the jaw. Journal of oral and maxillofacial surgery : official journal of the American Association of Oral and Maxillofacial Surgeons. 2009 Mar [PubMed PMID: 19231785]|
|||Sharma D,Ivanovski S,Slevin M,Hamlet S,Pop TS,Brinzaniuc K,Petcu EB,Miroiu RI, Bisphosphonate-related osteonecrosis of jaw (BRONJ): diagnostic criteria and possible pathogenic mechanisms of an unexpected anti-angiogenic side effect. Vascular cell. 2013 Jan 14 [PubMed PMID: 23316704]|
|||Fedele S,Porter SR,D'Aiuto F,Aljohani S,Vescovi P,Manfredi M,Arduino PG,Broccoletti R,Musciotto A,Di Fede O,Lazarovici TS,Campisi G,Yarom N, Nonexposed variant of bisphosphonate-associated osteonecrosis of the jaw: a case series. The American journal of medicine. 2010 Nov [PubMed PMID: 20851366]|
|||Pogrel MA, Bisphosphonates and bone necrosis. Journal of oral and maxillofacial surgery : official journal of the American Association of Oral and Maxillofacial Surgeons. 2004 Mar [PubMed PMID: 15015179]|
|||Ferlito S,Puzzo S,Liardo C, Preventive protocol for tooth extractions in patients treated with zoledronate: a case series. Journal of oral and maxillofacial surgery : official journal of the American Association of Oral and Maxillofacial Surgeons. 2011 Jun [PubMed PMID: 21316136]|
|||Scoletta M,Arduino PG,Pol R,Arata V,Silvestri S,Chiecchio A,Mozzati M, Initial experience on the outcome of teeth extractions in intravenous bisphosphonate-treated patients: a cautionary report. Journal of oral and maxillofacial surgery : official journal of the American Association of Oral and Maxillofacial Surgeons. 2011 Feb [PubMed PMID: 21129835]|
|||Barasch A,Cunha-Cruz J,Curro FA,Hujoel P,Sung AH,Vena D,Voinea-Griffin AE,Beadnell S,Craig RG,DeRouen T,Desaranayake A,Gilbert A,Gilbert GH,Goldberg K,Hauley R,Hashimoto M,Holmes J,Latzke B,Leroux B,Lindblad A,Richman J,Safford M,Ship J,Thompson VP,Williams OD,Yin W, Risk factors for osteonecrosis of the jaws: a case-control study from the CONDOR dental PBRN. Journal of dental research. 2011 Apr [PubMed PMID: 21317246]|
|||Schubert M,Klatte I,Linek W,Müller B,Döring K,Eckelt U,Hemprich A,Berger U,Hendricks J, The saxon bisphosphonate register - therapy and prevention of bisphosphonate-related osteonecrosis of the jaws. Oral oncology. 2012 Apr [PubMed PMID: 22130456]|
|||Saad F,Brown JE,Van Poznak C,Ibrahim T,Stemmer SM,Stopeck AT,Diel IJ,Takahashi S,Shore N,Henry DH,Barrios CH,Facon T,Senecal F,Fizazi K,Zhou L,Daniels A,Carrière P,Dansey R, Incidence, risk factors, and outcomes of osteonecrosis of the jaw: integrated analysis from three blinded active-controlled phase III trials in cancer patients with bone metastases. Annals of oncology : official journal of the European Society for Medical Oncology. 2012 May [PubMed PMID: 21986094]|
|||Allen MR,Pandya B,Ruggiero SL, Lack of correlation between duration of osteonecrosis of the jaw and sequestra tissue morphology: what it tells us about the condition and what it means for future studies. Journal of oral and maxillofacial surgery : official journal of the American Association of Oral and Maxillofacial Surgeons. 2010 Nov [PubMed PMID: 20869151]|
|||Sawatari Y,Marx RE, Bisphosphonates and bisphosphonate induced osteonecrosis. Oral and maxillofacial surgery clinics of North America. 2007 Nov [PubMed PMID: 18088900]|
|||Rosen HN,Moses AC,Garber J,Iloputaife ID,Ross DS,Lee SL,Greenspan SL, Serum CTX: a new marker of bone resorption that shows treatment effect more often than other markers because of low coefficient of variability and large changes with bisphosphonate therapy. Calcified tissue international. 2000 Feb [PubMed PMID: 10652955]|
|||Yamazaki T,Yamori M,Ishizaki T,Asai K,Goto K,Takahashi K,Nakayama T,Bessho K, Increased incidence of osteonecrosis of the jaw after tooth extraction in patients treated with bisphosphonates: a cohort study. International journal of oral and maxillofacial surgery. 2012 Nov [PubMed PMID: 22840716]|
|||Morag Y,Morag-Hezroni M,Jamadar DA,Ward BB,Jacobson JA,Zwetchkenbaum SR,Helman J, Bisphosphonate-related osteonecrosis of the jaw: a pictorial review. Radiographics : a review publication of the Radiological Society of North America, Inc. 2009 Nov [PubMed PMID: 19926757]|
|||Store G,Larheim TA, Mandibular osteoradionecrosis: a comparison of computed tomography with panoramic radiography. Dento maxillo facial radiology. 1999 Sep [PubMed PMID: 10490748]|
|||Bianchi SD,Scoletta M,Cassione FB,Migliaretti G,Mozzati M, Computerized tomographic findings in bisphosphonate-associated osteonecrosis of the jaw in patients with cancer. Oral surgery, oral medicine, oral pathology, oral radiology, and endodontics. 2007 Aug [PubMed PMID: 17560140]|
|||Stockmann P,Hinkmann FM,Lell MM,Fenner M,Vairaktaris E,Neukam FW,Nkenke E, Panoramic radiograph, computed tomography or magnetic resonance imaging. Which imaging technique should be preferred in bisphosphonate-associated osteonecrosis of the jaw? A prospective clinical study. Clinical oral investigations. 2010 Jun [PubMed PMID: 19513765]|
|||Bedogni A,Blandamura S,Lokmic Z,Palumbo C,Ragazzo M,Ferrari F,Tregnaghi A,Pietrogrande F,Procopio O,Saia G,Ferretti M,Bedogni G,Chiarini L,Ferronato G,Ninfo V,Lo Russo L,Lo Muzio L,Nocini PF, Bisphosphonate-associated jawbone osteonecrosis: a correlation between imaging techniques and histopathology. Oral surgery, oral medicine, oral pathology, oral radiology, and endodontics. 2008 Mar [PubMed PMID: 18280968]|
|||Elad S,Gomori MJ,Ben-Ami N,Friedlander-Barenboim S,Regev E,Lazarovici TS,Yarom N, Bisphosphonate-related osteonecrosis of the jaw: clinical correlations with computerized tomography presentation. Clinical oral investigations. 2010 Feb [PubMed PMID: 19603201]|
|||Phal PM,Myall RW,Assael LA,Weissman JL, Imaging findings of bisphosphonate-associated osteonecrosis of the jaws. AJNR. American journal of neuroradiology. 2007 Jun-Jul [PubMed PMID: 17569974]|
|||Schulze D,Blessmann M,Pohlenz P,Wagner KW,Heiland M, Diagnostic criteria for the detection of mandibular osteomyelitis using cone-beam computed tomography. Dento maxillo facial radiology. 2006 Jul [PubMed PMID: 16798917]|
|||Guerrero ME,Jacobs R,Loubele M,Schutyser F,Suetens P,van Steenberghe D, State-of-the-art on cone beam CT imaging for preoperative planning of implant placement. Clinical oral investigations. 2006 Mar [PubMed PMID: 16482455]|
|||Torres SR,Chen CS,Leroux BG,Lee PP,Hollender LG,Santos EC,Drew SP,Hung KC,Schubert MM, Mandibular cortical bone evaluation on cone beam computed tomography images of patients with bisphosphonate-related osteonecrosis of the jaw. Oral surgery, oral medicine, oral pathology and oral radiology. 2012 May [PubMed PMID: 22668629]|
|||Wilde F,Heufelder M,Lorenz K,Liese S,Liese J,Helmrich J,Schramm A,Hemprich A,Hirsch E,Winter K, Prevalence of cone beam computed tomography imaging findings according to the clinical stage of bisphosphonate-related osteonecrosis of the jaw. Oral surgery, oral medicine, oral pathology and oral radiology. 2012 Dec [PubMed PMID: 23159120]|
|||Chiandussi S,Biasotto M,Dore F,Cavalli F,Cova MA,Di Lenarda R, Clinical and diagnostic imaging of bisphosphonate-associated osteonecrosis of the jaws. Dento maxillo facial radiology. 2006 Jul [PubMed PMID: 16798918]|
|||Krishnan A,Arslanoglu A,Yildirm N,Silbergleit R,Aygun N, Imaging findings of bisphosphonate-related osteonecrosis of the jaw with emphasis on early magnetic resonance imaging findings. Journal of computer assisted tomography. 2009 Mar-Apr [PubMed PMID: 19346864]|
|||Popovic KS,Kocar M, Imaging findings in bisphosphonate-induced osteonecrosis of the jaws. Radiology and oncology. 2010 Dec [PubMed PMID: 22933918]|
|||Colston BW Jr,Everett MJ,Sathyam US,DaSilva LB,Otis LL, Imaging of the oral cavity using optical coherence tomography. Monographs in oral science. 2000 [PubMed PMID: 10949834]|
|||Hall A,Girkin JM, A review of potential new diagnostic modalities for caries lesions. Journal of dental research. 2004 [PubMed PMID: 15286130]|
|||Baumgartner A,Dichtl S,Hitzenberger CK,Sattmann H,Robl B,Moritz A,Fercher AF,Sperr W, Polarization-sensitive optical coherence tomography of dental structures. Caries research. 2000 Jan-Feb [PubMed PMID: 10601786]|
|||Ji X,Pushalkar S,Li Y,Glickman R,Fleisher K,Saxena D, Antibiotic effects on bacterial profile in osteonecrosis of the jaw. Oral diseases. 2012 Jan [PubMed PMID: 21883710]|
|||Woo SB,Hellstein JW,Kalmar JR, Narrative [corrected] review: bisphosphonates and osteonecrosis of the jaws. Annals of internal medicine. 2006 May 16 [PubMed PMID: 16702591]|
|||Ruggiero SL,Mehrotra B,Rosenberg TJ,Engroff SL, Osteonecrosis of the jaws associated with the use of bisphosphonates: a review of 63 cases. Journal of oral and maxillofacial surgery : official journal of the American Association of Oral and Maxillofacial Surgeons. 2004 May [PubMed PMID: 15122554]|
|||Melo MD,Obeid G, Osteonecrosis of the jaws in patients with a history of receiving bisphosphonate therapy: strategies for prevention and early recognition. Journal of the American Dental Association (1939). 2005 Dec [PubMed PMID: 16383049]|
|||Bashutski JD,Eber RM,Kinney JS,Benavides E,Maitra S,Braun TM,Giannobile WV,McCauley LK, Teriparatide and osseous regeneration in the oral cavity. The New England journal of medicine. 2010 Dec 16 [PubMed PMID: 20950166]|
|||Harper RP,Fung E, Resolution of bisphosphonate-associated osteonecrosis of the mandible: possible application for intermittent low-dose parathyroid hormone [rhPTH(1-34)]. Journal of oral and maxillofacial surgery : official journal of the American Association of Oral and Maxillofacial Surgeons. 2007 Mar [PubMed PMID: 17307613]|
|||Lau AN,Adachi JD, Resolution of osteonecrosis of the jaw after teriparatide [recombinant human PTH-(1-34)] therapy. The Journal of rheumatology. 2009 Aug [PubMed PMID: 19671824]|
|||Cheung A,Seeman E, Teriparatide therapy for alendronate-associated osteonecrosis of the jaw. The New England journal of medicine. 2010 Dec 16 [PubMed PMID: 20950167]|
|||Wilde F,Heufelder M,Winter K,Hendricks J,Frerich B,Schramm A,Hemprich A, The role of surgical therapy in the management of intravenous bisphosphonates-related osteonecrosis of the jaw. Oral surgery, oral medicine, oral pathology, oral radiology, and endodontics. 2011 Feb [PubMed PMID: 20674411]|
|||Bedogni A,Saia G,Bettini G,Tronchet A,Totola A,Bedogni G,Ferronato G,Nocini PF,Blandamura S, Long-term outcomes of surgical resection of the jaws in cancer patients with bisphosphonate-related osteonecrosis. Oral oncology. 2011 May [PubMed PMID: 21439892]|
|||Freiberger JJ,Padilla-Burgos R,McGraw T,Suliman HB,Kraft KH,Stolp BW,Moon RE,Piantadosi CA, What is the role of hyperbaric oxygen in the management of bisphosphonate-related osteonecrosis of the jaw: a randomized controlled trial of hyperbaric oxygen as an adjunct to surgery and antibiotics. Journal of oral and maxillofacial surgery : official journal of the American Association of Oral and Maxillofacial Surgeons. 2012 Jul [PubMed PMID: 22698292]|
|||Cella L,Oppici A,Arbasi M,Moretto M,Piepoli M,Vallisa D,Zangrandi A,Di Nunzio C,Cavanna L, Autologous bone marrow stem cell intralesional transplantation repairing bisphosphonate related osteonecrosis of the jaw. Head [PubMed PMID: 21849044]|
|||Mozzati M,Gallesio G,Arata V,Pol R,Scoletta M, Platelet-rich therapies in the treatment of intravenous bisphosphonate-related osteonecrosis of the jaw: a report of 32 cases. Oral oncology. 2012 May [PubMed PMID: 22265335]|
|||Vescovi P,Manfredi M,Merigo E,Meleti M,Fornaini C,Rocca JP,Nammour S, Surgical approach with Er:YAG laser on osteonecrosis of the jaws (ONJ) in patients under bisphosphonate therapy (BPT). Lasers in medical science. 2010 Jan [PubMed PMID: 19543768]|
|||Vescovi P,Merigo E,Meleti M,Manfredi M,Guidotti R,Nammour S, Bisphosphonates-related osteonecrosis of the jaws: a concise review of the literature and a report of a single-centre experience with 151 patients. Journal of oral pathology [PubMed PMID: 21958312]|
|||Adornato MC,Morcos I,Rozanski J, The treatment of bisphosphonate-associated osteonecrosis of the jaws with bone resection and autologous platelet-derived growth factors. Journal of the American Dental Association (1939). 2007 Jul [PubMed PMID: 17606496]|
|||Ruggiero SL,Fantasia J,Carlson E, Bisphosphonate-related osteonecrosis of the jaw: background and guidelines for diagnosis, staging and management. Oral surgery, oral medicine, oral pathology, oral radiology, and endodontics. 2006 Oct [PubMed PMID: 16997108]|
|||Ruggiero SL,Dodson TB,Assael LA,Landesberg R,Marx RE,Mehrotra B, American Association of Oral and Maxillofacial Surgeons position paper on bisphosphonate-related osteonecrosis of the jaw - 2009 update. Australian endodontic journal : the journal of the Australian Society of Endodontology Inc. 2009 Dec [PubMed PMID: 19961450]|
|||American Association of Oral and Maxillofacial Surgeons position paper on bisphosphonate-related osteonecrosis of the jaws. Journal of oral and maxillofacial surgery : official journal of the American Association of Oral and Maxillofacial Surgeons. 2007 Mar [PubMed PMID: 17307580]|
|||Khan AA,Sándor GK,Dore E,Morrison AD,Alsahli M,Amin F,Peters E,Hanley DA,Chaudry SR,Dempster DW,Glorieux FH,Neville AJ,Talwar RM,Clokie CM,Al Mardini M,Paul T,Khosla S,Josse RG,Sutherland S,Lam DK,Carmichael RP,Blanas N,Kendler D,Petak S,St-Marie LG,Brown J,Evans AW,Rios L,Compston JE, Canadian consensus practice guidelines for bisphosphonate associated osteonecrosis of the jaw. The Journal of rheumatology. 2008 Jul [PubMed PMID: 18528958]|
|||Dimopoulos MA,Kastritis E,Bamia C,Melakopoulos I,Gika D,Roussou M,Migkou M,Eleftherakis-Papaiakovou E,Christoulas D,Terpos E,Bamias A, Reduction of osteonecrosis of the jaw (ONJ) after implementation of preventive measures in patients with multiple myeloma treated with zoledronic acid. Annals of oncology : official journal of the European Society for Medical Oncology. 2009 Jan [PubMed PMID: 18689864]|
|||Ripamonti CI,Maniezzo M,Campa T,Fagnoni E,Brunelli C,Saibene G,Bareggi C,Ascani L,Cislaghi E, Decreased occurrence of osteonecrosis of the jaw after implementation of dental preventive measures in solid tumour patients with bone metastases treated with bisphosphonates. The experience of the National Cancer Institute of Milan. Annals of oncology : official journal of the European Society for Medical Oncology. 2009 Jan [PubMed PMID: 18647964]|
|||Montefusco V,Gay F,Spina F,Miceli R,Maniezzo M,Teresa Ambrosini M,Farina L,Piva S,Palumbo A,Boccadoro M,Corradini P, Antibiotic prophylaxis before dental procedures may reduce the incidence of osteonecrosis of the jaw in patients with multiple myeloma treated with bisphosphonates. Leukemia [PubMed PMID: 19021059]|
|||Hellstein JW,Adler RA,Edwards B,Jacobsen PL,Kalmar JR,Koka S,Migliorati CA,Ristic H, Managing the care of patients receiving antiresorptive therapy for prevention and treatment of osteoporosis: executive summary of recommendations from the American Dental Association Council on Scientific Affairs. Journal of the American Dental Association (1939). 2011 Nov [PubMed PMID: 22041409]|